Ottawa, Ontario – October 18, 2011 – Oncolytic virology uses live viruses to sense the genetic difference between a tumor and normal cell. Once the virus finds a tumor cell, it replicates inside that cell, kills it and then spreads to adjacent tumor cells to seed a therapeutic "chain reaction". As reported in today's issue of Cancer Cell, Dr. David Stojdl, a scientist from the Children's Hospital of Eastern Ontario Research Institute at the University of Ottawa has found a way to trick resistant cancer cells into committing suicide following oncolytic virus therapy.
When it comes to using oncolytic viruses to fight cancer, the outcome is a consequence of a battle between the genes that the virus has and the genes that the human host has. Using a technology called RNA Interference (RNAi) Dr. Stojdl's research team was able to systematically search through the entire human genome to find genes [that when inhibited] would make the viruses up to 10,000 times more potent at killing tumor cells without harming healthy cells. "Until now, scientists in our field have been focused on engineering the genes in the oncolytic virus itself to make them work better, and that has worked well to a point. This is the first study to look at all of the genes in the human genome to determine which ones we should manipulate to help the oncolytic therapy work better," said Dr. Stojdl.
Dr. Stojdl's research team has identified a series of genes that magnify the impact of oncolytic viruses. These genes normally control the endoplasmic reticulum stress response, or unfolded protein response. In essence, when the cell environment is toxic the cells have a tough time folding proteins. "A properly folded protein doesn't expose many sticky parts on its surface. Cells don't like mangled proteins because they get sticky. If you have sticky parts they combine with other proteins to make large, toxic 'balls' of protein - and this can kill the cell," explained Dr. Stojdl in layman terms.
"To deal with this 'sticky situation', the cell turns on a few pre-programmed rescue systems that either turbocharge the folding process or slow down the production of new proteins until the cell can catch up. If this doesn't work, the cell commits suicide to stop the damage from spreading," explained Dr. Douglas Mahoney lead author of the study and member of the Stojdl lab.
Dr. Stojdl's team has identified a way to short-circuit these rescue systems so that tumor cells go straight to suicide and healthy cells stay intact. The strategy works by applying a mild stress to the cells to force them to turn on these rescue systems. But when these cells encounter an oncolytic virus, instead of trying to fix the unfolded proteins, the cell is triggered to commit suicide.
This triggering effect also works with some common chemotherapeutics that are used in cancer clinics around the world today.
The funding partners for this research include: Terry Fox Foundation; Ottawa Regional Cancer Foundation; Angels of Hope; CHEO Foundation and Canada Foundation for Innovation.
About Dr. David Stojdl
Dr. David Stojdl is a scientist at the Children's Hospital of Eastern Ontario (Ottawa Canada), Assistant Professor in the Department of Pediatrics and cross-appointed to the Department of Biochemistry, Microbiology and Immunology at the University of Ottawa. He earned his bachelors (1992) and masters (1994) degrees in Microbiology and Immunology from the University of Western Ontario. In 1999 David obtained his PhD in the lab of John Bell (University of Ottawa) were he identified VSV as an oncolytic virus and defined the central role of interferon signaling in tumor specific targeting. As a post-doctoral fellow at the Ottawa Regional Cancer Centre (2000), Dr. Stojdl developed novel oncolytic viruses based on the VSV platform that have been adopted in labs worldwide. In 2004, Dr, Stojdl moved to the Children's Hospital of Eastern Ontario were his lab focuses on cell signaling and host/virus interactions with a special interest in continuing to develop oncolytic virus therapies for brain and pediatric cancer. Dr. Stojdl is co-director and developer of the high content cell-based screening facility at the CHEO RI and is a scientific cofounder of Jennerex Biotherapeutics (San Francisco, USA)
About the CHEO Research Institute:
Established in 1984, the CHEO Research Institute coordinates the research activities of the Children's Hospital of Eastern Ontario (CHEO) and is one of the institutes associated with the University of Ottawa Teaching Hospitals. The Research Institute brings together health professionals from within CHEO to share their efforts in solving paediatric health problems. It also promotes collaborative research outside the hospital with partners from the immediate community, industry and the international scientific world. For more information, visit www.cheori.org
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.